Navigation Links
Nicotine patches instead of cigarettes – New Year resolutio

A new resolution has been passed in United Kingdom which allows prescription of nicotine patches to children’s above the age of 12 and pregnant women as the risk associated with smoking is higher than the danger // associated with nicotine patches as earlier the sale of nicotine patches was not allowed to children’s, pregnant and breast feeding women and people with chronic diseases such as heart, liver and kidney diseases. The new amendment has also increased the prescription of nicotine patches from the duration of three months to nine months. Many leading pharmaceutical industries are preparing to manufacture Nicotine replacement therapies in the form of tablets, gums, lozenges and sprays. But critics feel that the cost of these nicotine patches are very high which could not be afford by students and the sale of these patches should be made available in all shops for easy access of the consumers.

'"/>




Page: 1

Related medicine news :

1. Kick Smoking with Nicotine Drink
2. Teens Misusing Nicotine-Replacement Products
3. Nicotine Vaccine May Help Smokers To Quit Smoking
4. Nicotine Patches help to quit smoking
5. Reliable Help For Smokers From Nicotine Patches and Former Smokers
6. So Called Benefits of Nicotine
7. Research Finds That Nicotine Hastens The Growth Of Lung Cancer
8. Is Nicotine Lozenge A Safe Smoking Cessation Product?
9. Nicotine - New Role in Prevention of Parkinson’s Diseas
10. Chantix: Disenchanting Smokers from Nicotine
11. Researchers Locate Genetic Link for Nicotine Dependence Among African Americans
Post Your Comments:
Breaking Medicine Technology:Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Finally a Health Care Option for Small Businesses 50925 1Finally a Health Care Option for Small Businesses 50925 22009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 12009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 22009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 3Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 1Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 2Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 3Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 4
Other Medicine Technology:Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 2Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 3Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 4Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 5Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 2Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 3Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 5Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 7Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 9Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 10